secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0000950170-23-042392
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics Reports Q2 2023 Results, Pipeline Progress with DT-216 and DT-168
--------------------------------------------------------------------------------

- Initial Phase 1 data for DT-216 in Friedreich Ataxia showed significant dose-related FXN mRNA increase in skeletal muscle (p<0.05)
- DT-216 Phase 1 MAD trial resumed in H2 2024 with improved formulation, data expected H1 2025
- IND submission for DT-168 for Fuchs Endothelial Corneal Dystrophy on track for H2 2023
- Cash and securities of $303.1M as of June 30, 2023, expected to fund operations through 2026
- Net loss of $19.9M for Q2 2023; R&D expenses $17.1M, G&A $5.5M

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000095017023042392/0000950170-23-042392-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000095017023042392/dsgn-20230814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-042392

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer